The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has published “Vaccine process technology—a decade of progress” in Biotechnology and Bioengineering. The paper serves as an update to a 2012 review titled “Vaccine process technology” authored by NIIMBL Executive Director Barry Buckland and explores transformations in vaccine development over the past decade.

Since 2012, the industry has seen advancements in DNA and RNA vaccine technologies, including the approval of 10 new viral vector and two new mRNA lipid nanoparticle vaccines. The COVID-19 pandemic further accelerated advancements for mRNA vaccines. Unlike traditional vaccines such as those which contain a weakened form of the target virus to trigger an immune response, or a surface protein, DNA and RNA vaccines carry instructions for cells to produce antigens. The review discusses the many innovations over the past 10 years in microbial fermentations, cell culture, cell-free systems, formulation, purification, stability, analytics, and changes in the regulatory landscape.

“The past 10 years have been a transformative time for vaccine development and production,” said Barry Buckland, NIIMBL Executive Director. “These advancements and continued progress over the next decade will allow the industry to bring new vaccines to the market to prevent many conditions. Progress in analytical characterization has been enabling these improvements.”

Since its launch in 2017, NIIMBL has invested in a portfolio of over 40 vaccine-focused collaborative projects, including the development of testbeds, formulation, stability, and analytics.

“It’s been exciting to work with our community of industry, academic, nonprofit and government partners to contribute to the innovations happening within the vaccines space,” said Kelvin Lee, NIIMBL Institute Director. “We are looking forward to more contributions in the years to come.”

Read “Vaccine process technology—a decade of progress” in Biotechnology and Bioengineering.

 

About NIIMBL

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry. NIIMBL is part of Manufacturing USA®, a diverse network of federally sponsored manufacturing innovation institutes, and is funded through a cooperative agreement with the National Institute of Standards and Technology (NIST) in the U.S. Department of Commerce with significant additional support from its members.

Source:
https://www.prnewswire.com/news-releases/niimbl-collaborates-on-review-of-vaccine-process-technology-developments-302157073.html
GMP mRNA
Check out our mRNA service to expedite your vaccine research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Future Of Gamma Delta T Cell Therapies

Gamma delta T cell-based immunotherapies have emerged as a promising frontier in cancer treatment and beyond, building on the success of chimeric antigen receptor T-cell (CAR T cell) therapy and expanding on the potential of the immune system as a therapeutic...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE